Jazz Pharmaceuticals plc (JAZZ) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $240.00, but acceptable to hold if already in. Reasons: Concentration risk — Product: Xywav (41.0%); Concentration risk — Supplier: ESSDS central pharmacy.
Jazz Pharmaceuticals is a global biopharma focused on rare diseases, with key products in sleep disorders (Xywav, Xyrem), epilepsy (Epidiolex), and oncology (Rylaze, Zepzelca, Ziihera, Modeyso). Revenue comes from pharmaceutical product sales globally, with Xywav at 41%,... Read more
Hold if already holding. Not a fresh buy at $240.00, but acceptable to hold if already in. Reasons: Concentration risk — Product: Xywav (41.0%); Concentration risk — Supplier: ESSDS central pharmacy. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 6.1/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Jazz Pharmaceuticals plc
Latest news
- M&T Bank Corp Purchases New Shares in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat — MarketBeat neutral
- Pictet Asset Management Holding SA Sells 33,547 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat — MarketBeat neutral
- Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Oncology Data, Cannabis Shift And Modeyso Royalty News - Sahm — Sahm neutral
- NBC5 In Depth: Curator of Burlington Discover Jazz Festival shares vision - WPTZ — WPTZ neutral
- How ASCO Phase 3 Oncology Data May Reshape Jazz Pharmaceuticals' (JAZZ) Investment Narrative - Yahoo Finance — Yahoo Finance positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductXywav41%10-K Item 1: 'In 2025, net product sales of Xywav were $1,657.0 million, which represented 41% of our total net product sales for the year.'
- MEDIUMProductEpidiolex26%10-K Item 1: 'Net product sales of Epidiolex/Epidyolex in 2025 were $1,059.2 million, which represented 26% of our total net product sales for the year.'
- LOWProductRylaze10%10-K Item 1: 'In 2025, net product sales of Rylaze were $402.9 million, which represented 10% of our total net product sales for the year.'
- HIGHSupplierESSDS central pharmacy10-K Item 1: 'Since 2002, we have had exclusive agreements with ESSDS, the central pharmacy for Xywav and Xyrem, to distribute Xywav and Xyrem in the U.S.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $240.00, but acceptable to hold if already in. Reasons: Concentration risk — Product: Xywav (41.0%); Concentration risk — Supplier: ESSDS central pharmacy. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $233.78 (-2.6%), stop $223.93 (−7.2%), A.R:R -0.6:1. Score 6.1/10, moderate confidence.
Take-profit target: $233.78 (-1.5% upside). Target $233.78 (-2.6%), stop $223.93 (−7.2%), A.R:R -0.6:1. Stop-loss: $223.93.
Concentration risk — Product: Xywav (41.0%); Concentration risk — Supplier: ESSDS central pharmacy; Analyst target reached - limited upside remaining.
Jazz Pharmaceuticals plc trades at a P/E of 2086.8 (forward 9.0). TrendMatrix value score: 7.1/10. Verdict: Hold.
24 analysts cover JAZZ with a consensus score of 4.3/5. Average price target: $242.
What does Jazz Pharmaceuticals plc do?Jazz Pharmaceuticals is a global biopharma focused on rare diseases, with key products in sleep disorders (Xywav,...
Jazz Pharmaceuticals is a global biopharma focused on rare diseases, with key products in sleep disorders (Xywav, Xyrem), epilepsy (Epidiolex), and oncology (Rylaze, Zepzelca, Ziihera, Modeyso). Revenue comes from pharmaceutical product sales globally, with Xywav at 41%, Epidiolex at 26%, Rylaze at 10%, and Zepzelca at 8% of 2025 net product sales. Xywav and Xyrem are distributed exclusively through ESSDS under a REMS program.